Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02278328 · ClinicalTrials.gov registry record · Early Phase 1
MEG Study of Acute STX209 Effects in ASD
A Early Phase 1 study of Autism Disorder, sponsored by Timothy Roberts.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02278328: Completed Early Phase 1 study of Autism Disorder, sponsored by Timothy Roberts.
NCT02278328 is a Early Phase 1 study of Autism Disorder that has completed, run by Timothy Roberts. The registered enrollment target is 25 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (53% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02278328, a Early Phase 1 study of Autism Disorder, has completed, sponsored by Timothy Roberts.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single-site, randomized, acute dose-response study to determine whether STX209 produces a dose-dependent significant change in MEG target parameters compared to baseline as well as compared to placebo treatment.
Primary Outcome
The latency of the M50 auditory evoked response component arising from the left cerebral hemisphere
Conditions Studied
Interventions
- DRUG placebo
- DRUG STX209 (15mg)
- DRUG STX209 (30mg)
Study Locations (1)
Pennsylvania
- Children's Hospital of Phladelphia - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2016-02 |
| Est. Completion | 2019-09-27 |
| Phase | Early Phase 1 |
What the finished NCT02278328 record still lists
NCT02278328 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Autism Disorder appearing as the primary indexed condition, and to 3 interventions - of which placebo is the first listed.
NCT02278328 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT02278328 about?
NCT02278328 is a clinical study titled "MEG Study of Acute STX209 Effects in ASD". This is a single-site, randomized, acute dose-response study to determine whether STX209 produces a dose-dependent significant change in MEG target parameters compared to baseline as well as compared to placebo treatment.
What is the current status of trial NCT02278328?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2016-02. Estimated completion is 2019-09-27.
What conditions does trial NCT02278328 study?
This clinical trial studies the following conditions: Autism Disorder.
What interventions are being tested in trial NCT02278328?
The interventions under investigation include: placebo (DRUG), STX209 (15mg) (DRUG), STX209 (30mg) (DRUG).
Who is sponsoring clinical trial NCT02278328?
This trial is sponsored by Timothy Roberts, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02278328 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Autism Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02278328's enrollment target sits among peer trials
25 1000th of 2000 higher than 965 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia